Hengrui Pharmaceutical announced that the company and its subsidiaries have received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for injectable HRS-7058 capsules, HRS-7058 tablets, SHR-9839, adbelizumab injections, bevacizumab injections, and SHR-A2102 for injections, and will conduct clinical trials in the near future. These drugs include the self-developed humanized antibody drug SHR-9839, the anti-PD-L1 monoclonal antibody adbelimab injection, humanized anti-VEGF monoclonal antibody bevacizumab injection, SHR-A2102 for injection of antibody drug conjugates targeting nectin-4, and the novel small molecule covalent inhibitor HRS-7058. The total R&D investment for these drugs is approximately 72.31 million yuan, 968.98 million yuan, 364.73 million yuan, 248.22 million yuan, and 63.91 million yuan, respectively. According to the requirements of relevant laws and regulations, after obtaining a clinical trial approval notice, these drugs still need to carry out clinical trials and be reviewed and approved by the State Drug Administration before they can be manufactured and marketed.

Hengrui Pharmaceutical announced that the company and its subsidiaries have received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for injectable HRS-7058 capsules, HRS-7058 tablets, SHR-9839, adbelizumab injections, bevacizumab injections, and SHR-A2102 for injections, and will conduct clinical trials in the near future. These drugs include the self-developed humanized antibody drug SHR-9839, the anti-PD-L1 monoclonal antibody adbelimab injection, humanized anti-VEGF monoclonal antibody bevacizumab injection, SHR-A2102 for injection of antibody drug conjugates targeting nectin-4, and the novel small molecule covalent inhibitor HRS-7058. The total R&D investment for these drugs is approximately 72.31 million yuan, 968.98 million yuan, 364.73 million yuan, 248.22 million yuan, and 63.91 million yuan, respectively. According to the requirements of relevant laws and regulations, after obtaining a clinical trial approval notice, these drugs still need to carry out clinical trials and be reviewed and approved by the State Drug Administration before they can be manufactured and marketed.